K M Samiur Rahman Sefat

Scientist, Conjugation Development

Role: Scientist i at Vaxcyte
Location: San Francisco, CA, US
LinkedIn followers: 500 followers

About K M Samiur Rahman Sefat

I\'m a dedicated researcher with a focus on vaccine development and bioprocessing. I have led two successful protein-subunit-based intranasal vaccine projects, that helped me develop skills in cell-line development, biomolecule characterization, downstream bioseparations and vaccine immunology. I\'m passionate about advancing biotechnology and open to collaborative opportunities in the field.

Experience

Scientist i
Vaxcyte
Jan 2025 — Present · San Francisco, CA, US
Conjugation Development

Education

University of Houston
Doctor of Philosophy - PhD, Chemical and Biomolecular Engineering
2019 — 2024
Bangladesh University of Engineering and Technology
Bachelor's degree, Chemical Engineering

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@vaxcyte.com
Personal email
•••••@•••••.com
Direct dial
+•• ••• ••• ••••

Unlock verified contacts

Free to start · No credit card required

Current company

Vaxcyte

Biotechnology Research · 580 employees · Founded 2013 · San Carlos, California, United States

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

vaxcyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

About K M Samiur Rahman Sefat

Experience

Scientist i

Education

University of Houston

Bangladesh University of Engineering and Technology

Find verified contacts for anyone on LinkedIn